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Preventingmalaria infectionthrough
vaccination requires preventing
every sporozoite inoculated by
mosquito bite: a major challenge
for Plasmodium falciparum.
[60_TD$DIFF]Plasmodiumvivaxsporozoitescon-
sist of tachysporozoites causing
primary infection and bradysporo-
zoites leading to relapses. We
hypothesise that a candidate
P. vivax vaccine with low efﬁcacy
against primary infection may sub-
stantially reduce transmission by
preventing relapses.Unvaccinated
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Figure 1. Example of a Bite from a [60_TD$DIFF]Plasmodium vivax Infectious Mosquito Inoculating 15 Sporozoites
Consisting of 10 Tachysporozoites That Immediately Develop into Exoerythrocytic Schizonts, and 5 Brady-
sporozoites That Develop into Hypnozoites[61_TD$DIFF].–> In an unvaccinated individual, the 10 tachysporozoites will
cause a single primary blood-stage infection, and the hypnozoites will cause up to ﬁve relapses. Some
hypnozoites may die within liver hepatocytes or activate in batches, giving rise to fewer than ﬁve relapses. In an
individual receiving a vaccine that immobilises 90% of sporozoites, the efﬁcacy against primary infection will be
0.910 = 35%. However, every hypnozoite immobilised may potentially lead to a relapse prevented, and
consequently an efﬁcacy against relapses of up to 90%.Considerable effort has been invested in
the development of pre-erythrocytic vac-
cines for the prevention of P. falciparum
infection, with several candidates demon-
strating signiﬁcant efﬁcacy against infec-
tion in controlled human malaria infection
(CHMI) studies [1]. One candidate vac-
cine, RTS,S/AS01, has recently com-
pleted phase 3 trials in young children
in sub-Saharan Africa [2], receiving a pos-
itive opinion from the EuropeanMedicines
Agency and recommended for pilot
implementation studies by the World
Health Organization. In the month follow-
ing vaccination, RTS,S/AS01 prevents
approximately 50% of infections in
malaria-naïve adults bymounting humoral
and cellular immune responses targeting
the circumsporozoite (CS) antigen [1].
Protection is strongly associated withvaccine-induced anti-CS IgG antibodies
[3] which are believed to immobilise spor-
ozoites, preventing their invasion from the
skin into blood vessels [4]. Based on the
delayed time to detectable blood-stage
parasitemia in vaccinated volunteers
who were not protected, it has been esti-
mated that RTS,S/AS01 immobilises 90–
95% of sporozoites, with the 5–10% of
breakthrough sporozoites being sufﬁcient
to allow infection half of the time [3].
Similarly to P. falciparum, infection with
P. vivax begins with the inoculation of
sporozoites from an infectious mosquito.
P. vivax sporozoites can be categorised
into tachysporozoites which immediately
develop into exoerythrocytic schizonts,
and bradysporozoites which develop
into hypnozoites where development is
arrested for weeks to years until activation
to cause relapses [5]. An antibody-medi-
ated pre-erythrocytic P. vivax vaccine is
likely to target both tachysporozoites and
bradysporozoites in the skin. Similarly to
P. falciparum, a single tachysporozoite
that evades the vaccine-induced immune
response will lead to a breakthrough
infection, thus we would expect low to
modest efﬁcacy against primary infectioneven for a vaccine that prevents a large
proportion of sporozoites. However, it is
possible that every bradysporozoite
immobilised may lead to a relapse pre-
vented, thus efﬁcacy against relapses
may be comparable to the proportion of
sporozoites prevented. This hypothesis is
illustrated further via the example in
Figure 1.
The contribution of relapses to sustaining
P. vivax transmission has been investi-
gated in epidemiological studies, with
studies incorporating treatment with
primaquine for the elimination of hypno-
zoites from the liver providing a particu-
larly rich source of information. In
treatment-reinfection studies in southeast
Asian and western Paciﬁc populations
exposed to P. vivax, where participants
were randomised to receive blood-stage
drugs (e.g., chloroquine or artemether-
lumefantrine) or blood-stage drugs plus
primaquine, it has been demonstrated
that approximately 80–90% of new infec-
tions are attributable to relapses [6,7].
This suggests that interventions that
target hypnozoites, either by elimination
from the liver through treatment or
preventing their development in theTrends in Parasitology, Month Year, Vol. xx, No. yy 1
TREPAR 1599 No. of Pages 3ﬁrst place, may cause substantial reduc-
tions in population-level transmission of
P. vivax.
The theoretical implications of using vac-
cination to inhibit the build-up of the hyp-
nozoite reservoir in a population were
investigated using a mathematical model
of within-host hypnozoite infection cou-
pled to a model of P. vivax transmission
between humans andmosquitoes [8]. We
consider a hypothetical nonwaning pre-
erythrocytic P. vivax vaccine with efﬁcacy
against primary infection of Vinf and efﬁ-
cacy against relapses of Vrel. Figure 2A
shows the effect of vaccination on the
individual-level in terms of the expected
reduction in time with blood-stageIndividual-level imp
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Figure 2. Simulations from aMathematical Model of the
vaccine can reduce the expected duration of blood-st
(primary or relapse) of 1 month are assumed. The dash
impact of a vaccination campaign with 70% coverage on
information online allowing for simulation with different
2 Trends in Parasitology, Month Year, Vol. xx, No. yyparasitemia. The duration of blood-stage
parasitemia is a proxy for the onwards
transmission potential to mosquitoes
because of the high degree of correlation
between P. vivax parasitemia and game-
tocytemia [9]. As approximately 80% of
infections are assumed to be attributable
to relapses, increasing Vrel is predicted to
cause large reductions in the time spent
with blood-stage parasitemia. The popu-
lation-level impact of a vaccination cam-
paign with 70% coverage is shown in
Figure 2B for a range of scenarios. A
vaccine that does not prevent relapses
is predicted to cause very limited reduc-
tions in P. vivax parasite prevalence. In
contrast, a vaccine with high efﬁcacy
against relapses is predicted to causeact (B) 
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population-level transmission. The R computer code fo
parameter values.substantial reductions in prevalence,
enough to interrupt transmission in the
simpliﬁed scenario represented here.
The potentially high efﬁcacy against relap-
ses of a vaccine with low to modest efﬁ-
cacy against primary infection, coupled
with the crucial role of relapses in sustain-
ing transmission, suggests that pre-eryth-
rocytic P. vivax vaccines be prioritised for
further investigation. However, a number
of factors may count against the outlined
hypothesis, primarily related to knowl-
edge gaps surrounding hypnozoites
and relapses. The factors governing com-
mitment of sporozoites to development
as schizonts or hypnozoites are not
understood. The precise numbers ofPopulaon-level impact
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lasmodium vivax Vaccine. (A) By preventing infection, a
inf = 50% and duration of each blood-stage infection
arasitemia in an unvaccinated individual. (B) Predicted
r generating this ﬁgure is provided in the[62_TD$DIFF], supplemental
TREPAR 1599 No. of Pages 3tachysporozoites and bradysporozoites
are not known, although it has been dem-
onstrated that the ratio of schizonts to
hypnozoites is strain-dependent [10]. In
a prescient but largely ignored analysis, a
group of Russian malariologists demon-
strated that the expected number of
relapses is dependent on the ratio of
tachysporozoites to bradysporozoites
[5]. Furthermore, the processes govern-
ing activation of hypnozoites to initiate
relapses are still poorly understood. If
hypnozoites activate independently
(e.g., without external triggers or quorum
sensing) this would suggest one relapse
prevented for every one hypnozoite pre-
vented. External triggers such as fevers
may lead to hypnozoite activation in
batches – in which case prevention of
relapse requires preventing every hypno-
zoite in the batch.
In addition to the limitations of our under-
standing of hypnozoites, there is consider-
able uncertainty of the mechanism of
action of pre-erythrocytic vaccines
against any Plasmodium parasite.
Whereas antibody-mediated responses
are likely to target sporozoites in the skin,
cell-mediated immune responses are
more likely to target liver-stage schiz-
onts. A vaccine-induced cell-mediated
response may not be able to target
a hypnozoite until after activation –
potentially greater than a year after the
initial infectious mosquito bite, and long
enough for signiﬁcant waning of vaccine-
induced immunity [1].In participants in malaria-therapy studies
reinfected with a homologous strain of
P. vivax, large reductions in blood-stage
parasite densities between primary and
secondary infections were observed
[11]. Given the correlation between
parasitemia and gametocytemia [9], this
suggests that a primary infection may
contribute proportionately more to
onwards transmission than a single
relapse. As such, there is a strong case
for the incorporation of additional blood-
stage antigens in a candidate vaccine to
reduce parasitemia and gametocytemia
in breakthrough infections. Acknowledg-
ing the limitations of our understanding
of the biology and vaccinology, past
experience of developing P. falciparum
vaccines with low to moderate efﬁcacy
against infection suggests that it is also
feasible to do so for P. vivax and subse-
quently investigate the impact on relap-
ses. However, there are few P. vivax
vaccine candidates currently under devel-
opment, based on a limited number of
antigens, with most projects still at a
preclinical phase [12]. It is important
that underinvestment doesn’t allow the
potential of P. vivax vaccines to continue
to be overlooked.[63_TD$DIFF]Supplemental Information
Supplemental information associated with this article
can be found [64_TD$DIFF]online at http://dx.doi.org/10.1016/j.pt.
2016.12.011.
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